Regen BioPharma, Inc. (RGBP)
USD 0.07
(-16.47%)
USD 0.07
(-16.47%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.46 Million USD | -191.02% |
| 2022 | 2.99 Million USD | -60.54% |
| 2021 | -6.39 Million USD | 4.19% |
| 2020 | 4.35 Million USD | 72.23% |
| 2019 | -753.75 Thousand USD | 55.29% |
| 2018 | -3.15 Million USD | 31.34% |
| 2017 | -2.45 Million USD | 68.13% |
| 2016 | - USD | -289.47% |
| 2015 | -2.18 Million USD | -180.14% |
| 2014 | -706.12 Thousand USD | -120.78% |
| 2013 | -35.2 Thousand USD | 0.0% |
| 2012 | 234.06 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -122.78 Thousand USD | -454.5% |
| 2024 Q2 | -101.07 Thousand USD | 69.15% |
| 2024 Q3 | -107.97 Thousand USD | -7.08% |
| 2023 Q3 | -58.91 Thousand USD | 25.28% |
| 2023 Q1 | -463.86 Thousand USD | -223.88% |
| 2023 Q2 | -78.84 Thousand USD | 83.0% |
| 2023 FY | - USD | -191.02% |
| 2023 Q4 | -309.08 Thousand USD | -424.67% |
| 2022 Q3 | -58.77 Thousand USD | 23.03% |
| 2022 Q4 | -143.22 Thousand USD | -143.67% |
| 2022 FY | - USD | -60.54% |
| 2022 Q1 | -43.58 Thousand USD | 97.82% |
| 2022 Q2 | -76.36 Thousand USD | -75.19% |
| 2021 Q3 | 1.83 Million USD | 14232.05% |
| 2021 Q2 | -12.97 Thousand USD | 29.8% |
| 2021 FY | - USD | 4.19% |
| 2021 Q1 | -18.48 Thousand USD | 2.27% |
| 2021 Q4 | -2 Million USD | -209.22% |
| 2020 Q4 | -18.9 Thousand USD | -15.75% |
| 2020 FY | - USD | 72.23% |
| 2020 Q3 | -16.33 Thousand USD | 58.47% |
| 2020 Q2 | -39.33 Thousand USD | 70.81% |
| 2020 Q1 | -134.73 Thousand USD | 28.26% |
| 2019 Q3 | -137.72 Thousand USD | 40.3% |
| 2019 Q4 | -187.82 Thousand USD | -36.38% |
| 2019 FY | - USD | 55.29% |
| 2019 Q1 | -197.53 Thousand USD | 62.84% |
| 2019 Q2 | -230.67 Thousand USD | -16.78% |
| 2018 Q3 | -125.7 Thousand USD | 71.72% |
| 2018 Q4 | -531.58 Thousand USD | -322.89% |
| 2018 FY | - USD | 31.34% |
| 2018 Q1 | -873.92 Thousand USD | -31.48% |
| 2018 Q2 | -444.54 Thousand USD | 49.13% |
| 2017 Q3 | -553.01 Thousand USD | 24.87% |
| 2017 Q4 | -664.66 Thousand USD | -20.19% |
| 2017 FY | - USD | 68.13% |
| 2017 Q1 | -2.45 Million USD | -1.16% |
| 2017 Q2 | -736.04 Thousand USD | 69.98% |
| 2016 Q1 | -1.85 Million USD | -254.38% |
| 2016 Q2 | -1.08 Million USD | 41.46% |
| 2016 Q3 | -2.34 Million USD | -116.15% |
| 2016 FY | - USD | -289.47% |
| 2016 Q4 | -2.42 Million USD | -3.39% |
| 2015 Q2 | -621.12 Thousand USD | -191.41% |
| 2015 FY | - USD | -180.14% |
| 2015 Q1 | -213.14 Thousand USD | 11.33% |
| 2015 Q4 | -522.73 Thousand USD | 15.84% |
| 2015 Q3 | -621.11 Thousand USD | 0.0% |
| 2014 FY | - USD | -120.78% |
| 2014 Q1 | -185.83 Thousand USD | -57.67% |
| 2014 Q3 | -157.86 Thousand USD | 7.16% |
| 2014 Q4 | -240.39 Thousand USD | -52.28% |
| 2014 Q2 | -170.04 Thousand USD | 8.5% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | -117.86 Thousand USD | -57.51% |
| 2013 Q2 | -70.5 Thousand USD | 0.0% |
| 2013 Q3 | -74.82 Thousand USD | -6.13% |
| 2013 FY | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 102.064% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 124.726% |
| SQZ Biotechnologies Company | -64.14 Million USD | 102.286% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 108.44% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 98.441% |
| Mesoblast Limited | -62.38 Million USD | 102.35% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 195.437% |
| Genus plc | 73.7 Million USD | 98.011% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 122.173% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 141.329% |
| Marizyme, Inc. | -34.28 Million USD | 104.276% |
| ContraFect Corporation | -64.99 Million USD | 102.255% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 116.712% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 132.388% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 204.576% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 155.435% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 163.084% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 382.978% |
| Accustem Sciences Inc. | -3.74 Million USD | 139.13% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 103.04% |
| EV Biologics, Inc. | -1.26 Million USD | 215.691% |
| Q BioMed Inc. | -617.62 Thousand USD | 337.353% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 58.96% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 331.806% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 164.17% |
| Biomind Labs Inc. | -1.03 Million USD | 241.7% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 85.158% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 120.471% |
| Skye Bioscience, Inc. | -13.54 Million USD | 110.821% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 198.557% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 5963.824% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 137.74% |
| IMV Inc. | -35.52 Million USD | 104.127% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 109.237% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 158.592% |
| GB Sciences, Inc. | -1.41 Million USD | 203.245% |
| Alpha Cognition Inc. | -9.7 Million USD | 115.104% |
| HST Global, Inc. | -5303.00 USD | 27743.9% |
| CSL Limited | 4.78 Billion USD | 99.969% |
| Halberd Corporation | -74.27 Thousand USD | 2073.581% |
| Enzolytics Inc. | -2.12 Million USD | 169.083% |
| Resverlogix Corp. | -11.74 Million USD | 112.485% |
| Affymax, Inc. | -14.29 Million USD | 110.255% |
| SYBLEU INC | -141.57 Thousand USD | 1135.492% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 147.86% |
| argenx SE | -216.02 Million USD | 100.679% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 102.649% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -20.457% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 197.802% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -286.955% |
| AVAX Technologies, Inc. | -6.11 Million USD | 123.982% |
| Zenith Capital Corp. | -8.6 Million USD | 117.034% |
| Genscript Biotech Corporation | -248.71 Million USD | 100.589% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 8514.879% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 159.921% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 932.814% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 103.698% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 150.684% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 240.107% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -21701.844% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 183.769% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 176.316% |
| BioStem Technologies, Inc. | -7.55 Million USD | 119.407% |
| ONE Bio Corp. | 13.61 Million USD | 89.231% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 909.527% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 171.267% |
| Agentix Corp. | -1.37 Million USD | 206.867% |
| LadRx Corporation | 412.28 Thousand USD | -255.57% |
| Cell Source, Inc. | -4.27 Million USD | 134.311% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 499.203% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 256.461% |
| NovAccess Global Inc. | -1.03 Million USD | 241.666% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 83.443% |
| Itoco Inc. | -1.86 Million USD | 178.436% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 486.164% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 231.358% |
| Kadimastem Ltd | -2.62 Million USD | 155.859% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 712.986% |
| CytoDyn Inc. | -18.02 Million USD | 108.131% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 1954.96% |
| Mobile Lads Corp. | -2.24 Million USD | 165.411% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 12087.538% |
| Qrons Inc. | -40.08 Thousand USD | 3757.484% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 401.837% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -177.942% |
| Rebus Holdings, Inc. | -951 Thousand USD | 254.149% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 238.036% |
| International Stem Cell Corporation | 202 Thousand USD | -625.721% |
| Bioxytran, Inc. | -3.82 Million USD | 138.374% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 2884.871% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 159.545% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 104.087% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 3357.68% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 153.541% |
| Neutra Corp. | -181.24 Thousand USD | 908.817% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 107.272% |
| PureTech Health plc | -11.62 Million USD | 112.608% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 107.272% |
| IXICO plc | -707 Thousand USD | 307.349% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 119.076% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 103.032% |
| CSL Limited | 4.73 Billion USD | 99.969% |
| Cellectis S.A. | -92.63 Million USD | 101.582% |